Comparative in vitro effects of AZT and extracts of Ocimum gratissimum, Ficus polita, Clausena anisata, Alchornea cordifolia, and Elaeophorbia drupifera against HIV-1 and HIV-2 infections

被引:80
作者
Ayisi, NK [1 ]
Nyadedzor, C [1 ]
机构
[1] Univ Ghana, Virol Unit, Noguchi Mem Inst Med Res, Legon, Ghana
关键词
medicinal plants; AZT; HIV-1; HIV-2; infections;
D O I
10.1016/S0166-3542(02)00166-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of Ocimum gratissimum (GHX-2), Ficus polita (GHX-6), Clausena anisata (GHX-7), Alchornea cordifolia (GHX-26), Elaeophorbia drupifera (GHX-27), and AZT on in vitro HIV-1 and HIV-2 replication and cytopathicity were compared. All plant extracts inhibited HIV-1 strain HTLVIIIB cytopathicity, the leaves of GHX-2 and the seeds of GHX-26 having high antiviral indices (110 and 90, respectively). Against HIV-2 strain GH1, the EC50 values ranged from <0.005 to 0.075 mg/ml when treatment was started at 40 min after virus adsorption. except for GHX-7 which showed only moderate activity and GHX-26 which had no activity. When treatment was delayed for 2 h. the plant extracts, unlike AZT, were still very effective against HIV-2. Likewise, only the plant extracts were able to attain EC90 values when high multiplicity of infection (MOI) with HIV-1 strain GH3 was used when treatment was delayed for 2 h. In Molt-4 cocultures with Molt-4/HIV. early cytopathic effect (CPE) of cell fusion was unaffected by AZT but was completely inhibited by all plants at noncytotoxic concentrations. In addition, GHX-27 was selectively toxic to Molt-4/HIV cells. The plant extracts also inhibited HIV-1 reverse transcriptase (RT) activity at EC50 Values of <0.01-0.03 mg/ml. HIV-1 proviral DNA copying as determined in a polymerase chain reaction. was completely inhibited by GHX-2 and GHX-6 at 0.011 and 0.015 mg/ml, respectively. GHX-26 and GHX-27 showed only Very moderate activity. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:25 / 33
页数:9
相关论文
共 52 条
[41]  
SKINNER GR, 1993, Patent No. 11779
[42]   INTEGRATION IS NOT NECESSARY FOR EXPRESSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEIN PRODUCTS [J].
STEVENSON, M ;
HAGGERTY, S ;
LAMONICA, CA ;
MEIER, CM ;
WELCH, SK ;
WASIAK, AJ .
JOURNAL OF VIROLOGY, 1990, 64 (05) :2421-2425
[43]   MANAGEMENT OF INFECTIOUS AND IMMUNOLOGICAL COMPLICATIONS OF ACQUIRED-IMMUNODEFICIENCY-SYNDROME (AIDS) - CURRENT AND FUTURE-PROSPECTS [J].
TUAZON, CU ;
LABRIOLA, AM .
DRUGS, 1987, 33 (01) :66-84
[44]  
UEMURA D, 1972, TETRAHEDRON LETT, P1387
[45]  
UEMURA D, 1971, TETRAHEDRON LETT, P3673
[46]  
UEMURA D, 1974, TETRAHEDRON LETT, P2529
[47]   Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection [J].
Vlietinck, AJ ;
De Bruyne, T ;
Apers, S ;
Pieters, LA .
PLANTA MEDICA, 1998, 64 (02) :97-109
[48]   VIRAL DYNAMICS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
WEI, XP ;
GHOSH, SK ;
TAYLOR, ME ;
JOHNSON, VA ;
EMINI, EA ;
DEUTSCH, P ;
LIFSON, JD ;
BONHOEFFER, S ;
NOWAK, MA ;
HAHN, BH ;
SAAG, MS ;
SHAW, GM .
NATURE, 1995, 373 (6510) :117-122
[49]  
WONGSTAAL F, 1990, VIROLOGY, P1525
[50]  
Yamasaki K, 1998, BIOL PHARM BULL, V21, P829, DOI 10.1248/bpb.21.829